Research Analysts’ Recent Ratings Updates for CIGNA (CI)

A number of firms have modified their ratings and price targets on shares of CIGNA (NYSE: CI) recently:

  • 1/14/2019 – CIGNA is now covered by analysts at Stephens. They set an “overweight” rating on the stock.
  • 1/7/2019 – CIGNA had its “buy” rating reaffirmed by analysts at Credit Suisse Group AG. They now have a $250.00 price target on the stock.
  • 1/6/2019 – CIGNA had its “buy” rating reaffirmed by analysts at Barclays PLC. They now have a $220.00 price target on the stock.
  • 1/4/2019 – CIGNA was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $208.00 price target on the stock. According to Zacks, “Shares of Cigna have outperformed its industry's growth in six months' time. The company  has completed the acquisition of Express Scripts, which should lead to long-term growth. A robust Global Supplemental business, growing Government business, increasing membership, and strong capital position are the other positives. Strong 2018 outlook reflects business strength.  However, increase in leverage, rise in operating expenses and suspension of share buyback  might weigh on earnings.”
  • 1/3/2019 – CIGNA was upgraded by analysts at Raymond James from a “market perform” rating to an “outperform” rating. They now have a $187.17 price target on the stock.
  • 1/3/2019 – CIGNA had its price target lowered by analysts at Wells Fargo & Co from $221.00 to $200.00. They now have a “market perform” rating on the stock.
  • 1/3/2019 – CIGNA was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Shares of Cigna have outperformed its industry's growth in six months' time. The company  has completed the acquisition of Express Scripts, which should lead to long-term growth. A robust Global Supplemental business, growing Government business, increasing membership, and strong capital position are the other positives. Strong 2018 outlook reflects business strength.  However, increase in leverage, rise in operating expenses and suspension of share buyback  might weigh on earnings.”
  • 1/3/2019 – CIGNA was upgraded by analysts at ValuEngine from a “sell” rating to a “hold” rating.
  • 1/2/2019 – CIGNA is now covered by analysts at Edward Jones. They set a “buy” rating on the stock.
  • 12/28/2018 – CIGNA was downgraded by analysts at ValuEngine from a “hold” rating to a “sell” rating.
  • 12/24/2018 – CIGNA is now covered by analysts at Edward Jones. They set a “buy” rating and a $181.30 price target on the stock.
  • 12/13/2018 – CIGNA is now covered by analysts at Morgan Stanley. They set an “overweight” rating and a $304.00 price target on the stock.
  • 11/19/2018 – CIGNA had its price target raised by analysts at Leerink Swann from $250.00 to $260.00. They now have an “outperform” rating on the stock.

CI stock opened at $192.91 on Monday. The company has a debt-to-equity ratio of 1.61, a quick ratio of 0.98 and a current ratio of 0.98. CIGNA Co. has a fifty-two week low of $163.02 and a fifty-two week high of $227.13. The company has a market cap of $46.36 billion, a P/E ratio of 18.44, a PEG ratio of 0.80 and a beta of 0.73.

CIGNA (NYSE:CI) last released its earnings results on Thursday, November 1st. The health services provider reported $3.84 earnings per share for the quarter, topping the Zacks’ consensus estimate of $3.45 by $0.39. CIGNA had a net margin of 6.15% and a return on equity of 23.31%. The firm had revenue of $11.45 billion for the quarter, compared to analyst estimates of $11.19 billion. During the same period in the prior year, the firm earned $2.83 earnings per share. The business’s quarterly revenue was up 10.3% compared to the same quarter last year. Analysts anticipate that CIGNA Co. will post 14.28 EPS for the current year.



In other CIGNA news, insider Jason D. Sadler sold 21,189 shares of the stock in a transaction that occurred on Friday, November 2nd. The shares were sold at an average price of $212.99, for a total value of $4,513,045.11. Following the transaction, the insider now directly owns 41,966 shares in the company, valued at $8,938,338.34. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director William D. Zollars sold 201 shares of the stock in a transaction that occurred on Friday, December 14th. The shares were sold at an average price of $210.84, for a total transaction of $42,378.84. The disclosure for this sale can be found here. Insiders have sold 24,215 shares of company stock worth $5,160,680 over the last 90 days. Insiders own 1.10% of the company’s stock.

A number of institutional investors have recently made changes to their positions in CI. Cognios Capital LLC boosted its holdings in shares of CIGNA by 13.9% in the second quarter. Cognios Capital LLC now owns 14,302 shares of the health services provider’s stock valued at $2,430,000 after acquiring an additional 1,741 shares during the period. FMR LLC lifted its holdings in shares of CIGNA by 10.8% during the second quarter. FMR LLC now owns 7,561,105 shares of the health services provider’s stock worth $1,285,010,000 after purchasing an additional 734,965 shares during the period. Baird Financial Group Inc. lifted its holdings in shares of CIGNA by 395.3% during the second quarter. Baird Financial Group Inc. now owns 6,315 shares of the health services provider’s stock worth $1,073,000 after purchasing an additional 5,040 shares during the period. Van ECK Associates Corp acquired a new stake in shares of CIGNA during the second quarter worth $694,000. Finally, Flagship Harbor Advisors LLC acquired a new stake in shares of CIGNA during the second quarter worth $102,000. Institutional investors own 93.36% of the company’s stock.

Cigna Corporation, a health services organization, provides insurance and related products and services in the United States and internationally. It operates through Global Health Care, Global Supplemental Benefits, Group Disability and Life, and Other Operations segments. The Global Health Care segment offers medical, dental, behavioral health, vision, and prescription drug benefit plans, as well as health advocacy programs, and other products and services to insured and self-insured customers.

Featured Story: How does a reverse stock split work?

Receive News & Ratings for CIGNA Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CIGNA Co and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply